Ovarian cancer trials in Spain

In Spain 90 Also abroad 802

90 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Sevilla
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 2Taking people
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Where
Alicante, Granada, Lugo, Madrid, Manresa, Reus, Sevilla, Valencia
Age
18 years and over
People
640 worldwide
Run by
North Eastern German Society of Gynaecological Oncology
See details and how to joinNCT05460000 · EU 2022-502559-69-01
Phase 1/2Taking people
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Where
A Coruña, Badalona, Barcelona, Córdoba, Elche, El Palmar, Girona, Lleida, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Rioja, Sabadell, Santander, Seville, Valencia, Zaragoza
Age
18 years and over
People
542 worldwide
Run by
Artios Pharma Ltd
See details and how to joinNCT04657068
Phase 1Taking people
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Where
Barcelona, Madrid
Age
18 years and over
People
138 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07360314 · EU 2025-523232-39-00
Phase 3Taking people
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Where
A Coruña, Barakaldo, Barcelona, Granollers, Madrid
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00
Phase 1/2Taking people
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Where
Barcelona, Logroño, Madrid, Pozuelo de Alarcón
Age
18 years and over
People
245 worldwide
Run by
BioNTech SE
See details and how to joinNCT07186842 · EU 2025-522613-26-00
Phase 3Taking people
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Where
Badalona, Barcelona, Madrid, Málaga, Oviedo, Palma, Pamplona, Sabadell, Sevilla, Valencia, Vitoria
Age
18 years and over
People
466 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07214779 · EU 2025-522748-42-00
Phase 1Taking people
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Where
Badalona, Barcelona, Madrid, Málaga, Pamplona, Zaragoza
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Where
A Coruña, Barcelona, Donostia, Girona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Santander, Sevilla, Valencia, Zaragoza
Age
18 years and over
People
400 worldwide
Run by
AbbVie
See details and how to joinNCT07059845 · EU 2025-521606-18-00
Phase 1Taking people
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Where
Barcelona, Madrid, Majadahonda
Age
18 years and over
People
285 worldwide
Run by
AbbVie
See details and how to joinNCT07278336 · EU 2025-522209-40-00
Phase 1Taking people
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Where
Barcelona, Madrid, Pamplona
Age
15 years and over
People
282 worldwide
Run by
Xencor, Inc.
See details and how to joinNCT06276491
No phaseNot yet taking people in Spain
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors
Where
Madrid
Age
18 years and over
People
32
Run by
Oncare Madrid
See details and how to joinNCT06139783
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Where
A Coruña, Badalona, Madrid, Málaga, Murcia, Palma, Sevilla, Vitoria
Age
18 years and over
People
544 worldwide
Run by
Genmab
See details and how to joinNCT07225270 · EU 2025-522167-15-00
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
A Coruña, Barcelona, Málaga, Pozuelo de Alarcón, Sant Cugat del Vallès, Sevilla
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Barcelona, Madrid, Málaga
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Barcelona, Madrid, Rioja, Valencia
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1Taking people
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Where
Barcelona, Logrono, Madrid
Age
18 years and over
People
32 worldwide
Run by
AstraZeneca
See details and how to joinNCT07402915 · EU 2025-522731-34-00
Phase 2/3Taking people
A clinical study of MK-5684 in people with certain solid tumors (MK-5684-015)
Where
A Coruña, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón
Age
18 years and over
People
22
Run by
Merck Sharp & Dohme LLC
See details and how to join2024-519563-18-00
Phase 1/2Taking people
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Where
Badalona, Barcelona, Girona, Madrid, Santiago de Compostela
Age
18 years and over
People
890 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00
Phase 1/2Taking people
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Where
Girona, Madrid, Santiago de Compostela
Age
18 years and over
People
612 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT04590326 · EU 2022-501904-83-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Barcelona, Córdoba, Madrid, Málaga, Sevilla
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 1/2Taking people
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Where
Barcelona, Madrid, Pamplona, Seville, Valencia, Zaragoza
Age
18 years and over
People
534 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06128551
Phase 1Taking people
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Where
Barcelona, Madrid, Piqueras, Seville
Age
18 years and over
People
540 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT05983432
Phase 1/2Taking people
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Where
Barcelona, Madrid
Age
18 years and over
People
250 worldwide
Run by
BioInvent International AB
See details and how to joinNCT04752826 · EU 2023-509847-29-00